Naveen Dakappagari

CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy

Anke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari et al. · The Journal of Immunology · 2007 · 176 citations · Full text

Immunology, Immune Regulation, New Approaches +18

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

Douglas B. Johnson, Jennifer Bordeaux, Ju Young Kim et al. · Clinical Cancer Research · 2018 · 174 citations

Immunology, Pathology, Immunotherapeutics +21

Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.

Naveen Dakappagari, Davina Douglas, Pierre L. Triozzi et al. · PubMed · 2000 · 113 citations

Mammary Tumors, Immunology, Immunodominance +20

2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)

Steven P. Piccoli, Devangi Mehta, Alessandra Vitaliti et al. · Bioanalysis · 2019 · 92 citations · Full text

Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy

Anke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari et al. · The Journal of Immunology · 2008 · 89 citations · Full text